Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
0.5mg PGE2 gel is a specific formulation of dinoprostone (prostaglandin E2) gel, a small molecule prostaglandin analog used for cervical ripening and the induction of labor. The active ingredient, dinoprostone, is a naturally occurring prostaglandin that acts as an agonist on prostaglandin EP receptors (specifically EP1, EP2, EP3, and EP4) in the uterus and cervix. This action stimulates uterine contractions and promotes cervical softening and ripening by breaking down collagen. A well-known brand name for this formulation is Prepidil, which is administered endocervically. It is utilized in clinical settings, such as in trials evaluating early versus delayed induction of labor in patients presenting with prelabor rupture of membranes (PROM) at term.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dinoprostone gel.